AI Medical Service INC. Announces FDA Breakthrough Device Designation for Endoscopic AI System

AI Medical Service Inc., one of the world’s first real-time endoscopic artificial intelligence (AI) developers, announced the Company has secured Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for its AI programs that analyze endoscopy images for potential diagnosis of gastric cancer. This designation will be critical as the Company continues to accelerate clinical and regulatory program especially in terms of prioritized review of the submission. At the same time as obtaining approval in its original country, Japan, the Company will continue to work through the regulatory process in the United States and other countries, and move on to global expansion.

Read More: Citi Partners with Software Fintech to Launch Refreshed Digital Investment Portal

Breakthrough Device Designation is granted to medical devices and device-led combination products that provide the potential for a more effective treatment option for life-threatening or irreversibly debilitating diseases. It expedites the traditional development, assessment and review process, and enables medical professionals to get access to new developments quickly.

Read More: Klaytn’s Fastest-Growing Blockchain Ecosystem: Numerous Global Exchanges, Wallets, and DApp Listing Sites Join Kakao’s Klaytn

AI Medical Service’s system applies neural network algorithms which are trained with large real-world datasets of images of biopsy-proven cancer lesions, benign lesions, and normal tissue that were captured using standard endoscopes, thus aiding physicians performing endoscopies to detect lesions suspicious for cancer. AI Medical’s technology is further differentiated as it is able to detect gastric, colorectal, and esophageal cancer, especially for concurrent usage whereas other entities’ technology tends to focus only on colorectal cancer.

Dr. Tomohiro Tada, CEO of AI Medical Services, says, “We will launch this groundbreaking technology approved by the FDA as soon as possible in the US market.  As our founding philosophy states, we plan to contribute to endoscopic medical treatment around the world.”

Read More: Premise Data Poised to Double in Size, Moves into Downtown Washington, D.C.